Item 7.01 Regulation FD Disclosure.
On
This information in this Item 7.01 of this Current Report on Form 8-K and in Exhibits 99.1 and 99.2 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
--------------------------------------------------------------------------------
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 99.1 Poster titled "GEM-3: Phase 3 Safety and Immunogenicity Results of beremagene geperpavec (B-VEC), an Investigational, Topical Gene Therapy for Dystrophic Epidermolysis Bullosa (DEB)" 99.2 ePoster presentation titled "GEM-3: Phase 3 Safety and Immunogenicity Results of beremagene geperpavec (B-VEC), an Investigational, Topical Gene Therapy for Dystrophic Epidermolysis Bullosa (DEB)" 104 Cover Page Interactive Data file (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source